AWM
TVTX icon

Avior Wealth Management’s Travere Therapeutics TVTX Stock Holding History

Avior Wealth Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14
Closed -$107 – 3638
2024
Q1 		$107 Buy
+14
New +$118 ﹤0.01% 3163

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Avior Wealth Management's TVTX Position: Q2 2024 in Review

Avior Wealth Management sold out of Travere Therapeutics (TVTX) in Q2 2024, closing a stake of 14 shares — an estimated $107 sold.

Avior Wealth Management first reported a position in TVTX in Q1 2024 and held it in 1 quarter. The position peaked at $107 in Q1 2024. 173 funds tracked by Wall St. Rank hold TVTX as of Q2 2024.

  • Avior Wealth Management reported no remaining Travere Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 14 Travere Therapeutics shares in Q2 2024, an estimated $107.
  • Avior Wealth Management first reported a position in Travere Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Travere Therapeutics position peaked at $107 in Q1 2024.
  • 173 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.